Table of Content

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview
Overview
Metastatic or Recurrent Cancer Treatment Types
Surgery
Chemotherapy
Radiotherapy
Targeted Therapy
Cancer Immunotherapies
Oncolytic Virotherapy
Antibody-Drug Conjugates
Porter’s Five Forces Analysis in the Oncology Market
Potential of New Entrants
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of Substitute Products or Services
Industry Rivalry: High

Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Robust Approval of Oncology Drugs
Technological Advances in Cancer Treatments
Increasing Incidence of Cancer Disease
Market Restraints
Loss of Exclusivity and Genericization
Lack of Oncology Professionals
Market Opportunities
Incorporation of Artificial Intelligence in Oncology
Promising Drugs in the Late Stage of the Pipeline

Chapter 4 Regulatory Landscape
The U.S. Approval Process
FDA Regulatory Considerations for Oncology Drug Development
European Union Approval Process
Current Situation in E.U. Approval Process
Japanese Approval Process

Chapter 5 Emerging Trends and Pipeline Analysis
Emerging Technologies
Personalized Cancer Vaccines
Test to Identify 18 Early-Stage Cancers
CAR T-Cell Therapy
Artificial Intelligence
Tablet to Cut Breast Cancer Risk
Nanoparticles
Pressurized Intraperitoneal Aerosol Chemotherapy
Cervical Cancer Treatment Breakthrough
New Developments
Biosimilar Approvals
Pipeline Analysis
Clinical Trial Analysis
Patent Analysis
Key Takeaways

Chapter 6 Supply Chain Analysis
Overview
Research and Development
Manufacturing
Packaging
Wholesale Distributors and Repackagers
Pharmacies
Dispensed to Consumers
Cancer Drug Shortage
Costs
Manufacturing Complexity
Geographic Concentration
Quality

Chapter 7 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis, by Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Liver Cancer
Cervix Cancer
Bladder Cancer
Kidney Cancer
Pancreatic Cancer
Ovarian Cancer
All Other Cancers
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 8 Competitive Intelligence
Overview
Blockbuster Oncology Pharmaceutical Brands
Global Market Shares of Leading Companies

Chapter 9 Sustainability in Cancers Therapeutics Market Emphasis on Recurrent and Metastatic Divisions: ESG Perspective
Role of ESG in the Pharma Industry
ESG Performance Analysis
Environmental Factors
Social Issues
Governance Factors
ESG Risk Ratings
Conclusion

Chapter 10 Appendix
Methodology
Emerging Start-ups/Market Disruptors
Sources
Abbreviations
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.



List of Figures


Summary Figure : Global Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, 2023
Figure 1 : Porter’s Five Forces Analysis of the Oncology Market
Figure 2 : Market Dynamics of the Global Cancer Therapeutics Market Emphasis on Recurrent and Metastatic Divisions
Figure 3 : Novel Oncology Drugs with FDA Approvals, 2016?2024
Figure 4 : U.S. Cancer Incidence, 2000?2021
Figure 5 : Share of Incidence Cases of All Cancer Types, Both Sexes, by WHO Region, 2022
Figure 6 : Oncology Drug Clinical Trial Studies, by Trial Phase, 2021?July 2024
Figure 7 : Phase 3 and 4 Clinical Trial Studies of Oncology Drugs for Metastatic and Recurrent Division, by Company, July 2024
Figure 8 : Top Applicants in Metastatic Cancer Patents, 2022?2024
Figure 9 : Supply Chain Process of Pharmaceutical Drugs
Figure 10 : Global Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, 2023
Figure 11 : Global Market Share of Lung Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 12 : Global Market Share of Breast Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 13 : Global Market Share of Colorectal Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 14 : Global Market Share of Prostate Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 15 : Global Market Share of Stomach Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 16 : Global Market Share of Liver Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 17 : Global Market Share of Cervical Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 18 : Global Market Share of Bladder Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 19 : Global Market Share of Kidney Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 20 : Global Market Share of Pancreatic Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 21 : Global Market Share of Ovarian Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 22 : Global Market Share of All Other Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 23 : Global Market Share of Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, 2023
Figure 24 : North American Market Share of Cancers Therapeutics Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
Figure 25 : Share of Cancer Incidence Cases in Europe, Both Sexes, by Cancer Type, 2022
Figure 26 : Share of Cancer Mortality Cases in Europe, Both Sexes, by Cancer Type, 2022
Figure 27 : European Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
Figure 28 : U.K. Current and Forecast Cancer Prevalence, 2020?2040
Figure 29 : Asia-Pacific and Oceania Share of Cancer Incidence, Both Sexes, 2022
Figure 30 : Asia-Pacific and Oceania Share of Cancer Mortality, Both Sexes, 2022
Figure 31 : Asia-Pacific Market Share of Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, 2023
Figure 32 : Top 10 Blockbuster Oncology Pharmaceutical Drugs, by Sales Revenue, 2023
Figure 33 : Company Share Analysis of Oncology Pharmaceutical Manufacturers, 2023
Figure 34 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 35 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 36 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
Figure 37 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 38 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
Figure 39 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
Figure 40 : Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 41 : Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 42 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
Figure 43 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 44 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 45 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 46 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 47 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 48 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
Figure 49 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
Figure 50 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 51 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 52 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
Figure 53 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
Figure 54 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 55 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 56 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 57 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 58 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 59 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
Figure 60 : Sanofi: Revenue Share, by Business Unit, FY 2023
Figure 61 : Sanofi: Revenue Share, by Country/Region, FY 2023
Figure 62 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 63 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023

List of Tables

 

Summary Table : Global Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 1 : Typical Various Metastatic Cancer Treatments
Table 2 : Promising Drugs in Late Stage of Pipeline, 2023
Table 3 : FDA Drug Approvals in Oncology, 2021?2023
Table 4 : Oncology Drug Approvals, 2020?July 2024
Table 5 : Novel Oncology Drug Approvals for Relapsed or Metastatic Cancers, 2021?November 2024*
Table 6 : FDA Approved Biosimilar for Oncology Indications, 2015?2024
Table 7 : FDA Approved Biosimilars and Interchangeable Biosimilars, by FDA, July 2024
Table 8 : EMA Approved Biosimilar for Oncology Indications, 2007?July 2024
Table 9 : Clinical Trial Drugs for Metastatic Cancers in Phases 3 and 4, 2024
Table 10 : Granted Patents in Metastatic Cancer Field, 2022?2024
Table 11 : Global Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 12 : Clinical Trial Study for Metastatic Lung Cancer, 2024
Table 13 : Global Market for Lung Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 14 : Common Drugs Used to Treat Metastatic Breast Cancer, 2023
Table 15 : Clinical Trial Studies for Metastatic Breast Cancer, 2024
Table 16 : Global Market for Breast Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 17 : Clinical Trial Study for Metastatic Colorectal Cancer, 2024
Table 18 : Global Market for Colorectal Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 19 : Clinical Trial Study for Metastatic Prostate Cancer, 2024
Table 20 : Global Market for Prostate Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 21 : Clinical Trial Study for Metastatic Stomach Cancer, 2024
Table 22 : Global Market for Stomach Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 23 : Clinical Trial Study for Metastatic Liver Cancer, 2024
Table 24 : Global Market for Liver Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 25 : Clinical Trial Study for Metastatic Cervical Cancer, 2024
Table 26 : Global Market for Cervical Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 27 : Clinical Trial Study for Metastatic Bladder Cancer, 2024
Table 28 : Global Market for Bladder Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 29 : Clinical Trial Study for Metastatic Kidney Cancer, 2024
Table 30 : Global Market for Kidney Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 31 : Clinical Trial Study for Metastatic Pancreatic Cancer, 2024
Table 32 : Global Market for Pancreatic Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 33 : Clinical Trial Study for Metastatic Ovarian Cancer, 2024
Table 34 : Global Market for Ovarian Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 35 : Global Market for All Other Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 36 : Global Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Region, Through 2029
Table 37 : North American Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 38 : North American Market for Cancers Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
Table 39 : Incidence and Mortality of Cancer Cases in the U.S., Both Sexes, 2024
Table 40 : U.S. Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 41 : Canadian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 42 : Incidence and Mortality of Cancer Cases in Mexico, Both Sexes, 2022
Table 43 : Mexican Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 44 : European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 45 : European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
Table 46 : Incidence and Mortality of Cancer Cases in Germany, Both Sexes, 2022
Table 47 : German Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 48 : U.K. New Diagnosed Cancer Cases, 2021 and 2022
Table 49 : U.K. Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 50 : Cancer Incidence and Mortality Cases in Franch, Both Sexes, 2022
Table 51 : French Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 52 : Cancer Incidence and Mortality Cases in Spain, Both Sexes, 2022
Table 53 : Spanish Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 54 : Cancer Incidence and Mortality Cases in Italy, Both Sexes, 2022
Table 55 : Italian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 56 : Rest of the European Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 57 : Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 58 : Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Country, Through 2029
Table 59 : Cancer Incidence and Mortality in China, Both Sexes, 2022
Table 60 : Chinese Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 61 : Japanese Cancer Incidence and Mortality, Both Sexes, 2022
Table 62 : Japanese Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 63 : Cancer Incidence and Mortality Cases in India, Both Sexes, 2022
Table 64 : Indian Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 65 : Cancer Incidence and Mortality Cases in South Korea, Both Sexes, 2022
Table 66 : South Korean Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 67 : Rest of Asia-Pacific Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 68 : Rest of World Market for Cancer Therapeutics with Emphasis on Recurrent and Metastatic Divisions, by Cancer Type, Through 2029
Table 69 : Drug Pipeline for Major Companies for Metastatic or Relapsed Condition, 2023
Table 70 : ESG Risk Rankings for Oncology Pharmaceuticals Companies, Through January 2025
Table 71 : List of a Few Emerging Startups
Table 72 : Report Information Sources
Table 73 : Abbreviations Used in the Global Cancer Therapeutics Market with Emphasis on Recurrent and Metastatic Divisions
Table 74 : AbbVie Inc.: Company Snapshot
Table 75 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 76 : AbbVie Inc.: Product Portfolio
Table 77 : AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 78 : Amgen Inc.: Company Snapshot
Table 79 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 80 : Amgen Inc.: Product Portfolio
Table 81 : Amgen Inc.: News/Key Developments, 2022–2024
Table 82 : AstraZeneca: Company Snapshot
Table 83 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 84 : AstraZeneca: Product Portfolio
Table 85 : AstraZeneca: News/Recent Developments, 2022?2024
Table 86 : Bayer AG: Company Snapshot
Table 87 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 88 : Bayer AG: Product Portfolio
Table 89 : Bayer AG: News/Key Developments, 2023–2024
Table 90 : Bristol-Myers Squibb Co.: Company Snapshot
Table 91 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 92 : Bristol-Myers Squibb Co.: Product Portfolio
Table 93 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 94 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 95 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 96 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 97 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022–2024
Table 98 : Gilead Sciences Inc.: Company Snapshot
Table 99 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 100 : Gilead Sciences Inc.: Product Portfolio
Table 101 : Gilead Sciences Inc.: News/Key Developments, 2022?2024
Table 102 : Johnson & Johnson Services Inc.: Company Snapshot
Table 103 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 104 : Johnson & Johnson Services Inc.: Product Portfolio
Table 105 : Johnson & Johnson Services Inc.: News/Key Developments, 2022?2024
Table 106 : Lilly: Company Snapshot
Table 107 : Lilly: Financial Performance, FY 2022 and 2023
Table 108 : Lilly: Product Portfolio
Table 109 : Lilly: News/Key Developments, 2023 and 2024
Table 110 : Merck & Co. Inc.: Company Snapshot
Table 111 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 112 : Merck & Co. Inc.: Product Portfolio
Table 113 : Merck & Co. Inc.: News/Key Developments, 2021–2024
Table 114 : Novartis AG: Company Snapshot
Table 115 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 116 : Novartis AG: Product Portfolio
Table 117 : Novartis AG: News/Key Developments, 2022-2024
Table 118 : Pfizer Inc.: Company Snapshot
Table 119 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 120 : Pfizer Inc.: Product Portfolio
Table 121 : Pfizer Inc.: News/Key Developments, 2021–2024
Table 122 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 123 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 124 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 125 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022–2024
Table 126 : Sanofi: Company Snapshot
Table 127 : Sanofi: Financial Performance, FY 2022 and 2023
Table 128 : Sanofi: Product Portfolio
Table 129 : Sanofi: News/Key Developments, 2022–2024
Table 130 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 131 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 132 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 133 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2021–2024